Adamas to Present at Upcoming Evercore ISI and Piper Jaffray Investor Conferences

Nov 21, 2019

EMERYVILLE, Calif., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders, today announced that Neil F. McFarlane, the Company’s Chief Executive Officer, is scheduled to present at the following investor conferences:

  • Evercore ISI 2nd Annual HealthCONx Conference on Tuesday, December 3 at 9:50 a.m. ET
    (6:50 a.m. PT)
  • Piper Jaffray 31st Annual Healthcare Conference on Wednesday, December 4 at 4:00 p.m. ET
    (1:00 p.m. PT)

The presentation will be webcast live from the investor relations section of the Adamas website at An archived version of the webcast will be available via replay for 30 days following the presentations.

About Adamas Pharmaceuticals, Inc.
Adamas’ goal is to create and commercialize a new generation of medicines intended to lessen the burden of chronic neurologic diseases on patients, caregivers and society using its deep understanding of time-dependent biology. The Company is focused on the commercialization of GOCOVRI® (amantadine) extended release capsules, the first and only FDA-approved medicine for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. The Company also continues to deliver differentiated investigational programs, including ADS-5102 in development for the treatment of walking impairment in patients with multiple sclerosis. For more information about Adamas and its unique approach to developing medicines based on time-dependent biology, please visit


Peter Vozzo
Managing Director, Westwicke

Sarah Mathieson
Vice President of Corporate Communications